MedTrace Logo

Acute Revascularization Treatment in Ischemic Stroke Patients With COVID-19

NCT04895462 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15128

Last updated 2023-03-08

No results posted yet for this study

Summary

Case-series and cohort studies have shown the feasibility of reperfusion therapies in patients with ischemic stroke and COVID-19, but due to the absence of a contemporary control group of non-COVID-19 patients, small sample size or lack of long-term outcome assessment, concerns regarding safety and efficacy of these treatments remain to be clarified. Taking into account its limitations, some studies documented higher rates of endovascular treatment complications such as clot fragmentation with distal embolization and vessel re-oclusion, to be more difficult to achieve recanalization after endovascular treatment, and higher rates of any intracerebral hemmorhage.

The investigators aim is to assess in a large, multicenter and international cohort, the safety and outcomes of acute reperfusion therapies in patients with ischemic stroke and COVID-19, by comparison with a contemporary control group of patients with ischemic stroke and without COVID-19 from the same centers.

Conditions

Sponsors & Collaborators

  • Larissa University Hospital

    collaborator OTHER

  • Society of Vascular and Interventional Neurology

    collaborator UNKNOWN

  • Hospital de Egas Moniz

    collaborator OTHER

  • Centre Hospitalier Universitaire Vaudois

    lead OTHER

Principal Investigators

  • João Pedro Marto, MD · Stroke Center, Department of Neurology, Lausanne University Hospital, Lausanne, Switzerland and Deparment of Neurology, Hospital de Egas Moniz, Lisbon, Portugal

  • George Ntaios, MD, PhD · Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

  • Davide Strambo, MD · Stroke Centre, Neurology Service, Lausanne University Hospital, Lausanne, Switzerland

  • Patrik Michel, MD · Stroke Centre, Neurology Service, Lausanne University Hospital, Lausanne, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2021-08-31
Completion
2021-10-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04895462 on ClinicalTrials.gov